Literature DB >> 21623752

High-concentration all-trans retinoic acid induces dermal inflammation and reduces the accumulation of type I procollagen in human skin in vivo.

H S Yoon1, Y K Kim, J H Chung.   

Abstract

BACKGROUND: Because inflammation is a factor promoting ageing, all-trans retinoic acid (RA)-induced irritation may have a negative influence on collagen accumulation in human skin despite its stimulation of collagen production.
OBJECTIVES: To determine whether RA-induced irritation detrimentally affects RA efficacy as represented by new collagen synthesis.
METHODS: Retinoic acid (0·01%, 0·025% or 0·05%) or vehicle was applied to the buttock skin of elderly male volunteers three times a week for 8 weeks under continuous occlusion. Every 2 weeks, biopsy specimens were obtained and immunohistochemical analysis was performed to determine levels of type I procollagen expression and inflammatory cell infiltration.
RESULTS: Topical RA regardless of concentration increased type I procollagen expression in human skin in vivo after 2 weeks. However, only 0·01% RA continuously increased type I procollagen expression up to 8 weeks. After 4 weeks, significant infiltrations of macrophages and neutrophils were observed in 0·025% and 0·05% RA-treated skin, and procollagen expression had returned to baseline.
CONCLUSIONS: Excessive RA-induced inflammation might prevent collagen accumulation in aged skin despite the positive effect of RA on collagen production.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623752     DOI: 10.1111/j.1365-2133.2011.10435.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  1 in total

1.  LE135, a retinoid acid receptor antagonist, produces pain through direct activation of TRP channels.

Authors:  Shijin Yin; Jialie Luo; Aihua Qian; Weihua Yu; Hongzhen Hu
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.